RxDoctor Payments Data

Hua Yang, MD

Clinical Cardiac Electrophysiology · Flushing, NYNPI 1215199765

Payments from drug & device makers

$2,687in general payments, 2019–2025

Across 73 payments — averaging $36.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Biotronik Inc.$751
  • Boston Scientific$601
  • EBR Systems, Inc.$449
  • Johnson & Johnson$166
  • Atricure, Inc.$158
  • Novartis$124
  • plus $438 from 9 others

What the payments were for

  • Food & beverage$2,687100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,687 in reported general payments places this provider in the 10th percentile of 214 clinical cardiac electrophysiology providers in New York.

See all clinical cardiac electrophysiology providers in New York

Medicare billing

Part B allowed, 2024
$190,577
Medicare patients
593
Services billed
2,056

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban673$535,203
MultaqDronedarone Hcl223$219,169
XareltoRivaroxaban116$99,981
EntrestoSacubitril/Valsartan55$42,131
Metoprolol Succinate343$3,778
SotalolSotalol Hcl66$1,053
Diltiazem 24hr Er (Cd)Diltiazem Hcl63$914
Amiodarone Hcl65$772
Metoprolol Tartrate78$416
Spironolactone29$235
Carvedilol33$231
Furosemide41$157
Flecainide Acetate12$99
Amlodipine Besylate19$87
Losartan Potassium19$58

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$122$535,203673 claims
Sanofi-aventis U.S. LLCMultaq$88$219,169223 claims
Johnson & JohnsonXarelto$166$99,981116 claims
NovartisEntresto$124$42,13155 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 10th percentile of 214 clinical cardiac electrophysiology providers in New York.

Other clinical cardiac electrophysiology in Flushing

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →